# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Truist Securities analyst Joon Lee reiterates Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from...
Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medicat...
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Corcept Therapeutics (NASDAQ:CORT) with a Buy and maintain...
Corcept Therapeutics announced the GRACE Phase 3 trial results for relacorilant in Cushing's syndrome, showing significant ...
CORT: 41% | Corcept Therapeutics shares are trading higher after the company announced that its Phase 3 GRACE trial met its pri...